Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03781167 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 244
- Enrollment target
NCT03781167 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 244 participants.
The verdict
NCT03781167, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 244 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety and tolerability of ABBV-951 (Foslevodopa/Foscarbidopa) in participants with Parkinson's disease (PD). This was a single-arm study with preplanned analyses conducted by dose subgroup (Low Dose or High Dose) based on the modal total daily dose (most frequent dose) over the treatment period.
Interventions
- DRUG ABBV-951
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2019-04-29 |
| Est. Completion | 2022-08-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03781167
The ClinicalTrials.gov registry entry for NCT03781167 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABBV-951 is the first listed.
NCT03781167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03781167 about?
NCT03781167 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)". The purpose of this study was to assess the safety and tolerability of ABBV-951 (Foslevodopa/Foscarbidopa) in participants with Parkinson's disease (PD). This was a single-arm study with preplanned analyses conducted by dose subgroup (Low Dose or High Dose) based on the modal total daily dose (most...
What is the current status of trial NCT03781167?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 244 participants. The study started on 2019-04-29. Estimated completion is 2022-08-17.
What interventions are being tested in trial NCT03781167?
The interventions under investigation include: ABBV-951 (DRUG).
Who is sponsoring clinical trial NCT03781167?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.